FDA grants market clearance for PLSG Medrobotics’ Flex Robotic system

4 August 2015 (Last Updated August 4th, 2015 18:30)

The US Food and Drug Administration (FDA) has authorised Medrobotics to market its Flex Robotic system in the US.

The US Food and Drug Administration (FDA) has authorised Medrobotics to market its Flex Robotic system in the US.

Pittsburgh Life Sciences Greenhouse (PLSG) is a pure life sciences investment firm, and includes Medrobotics as one of its portfolio companies.

The system offers physicians the ability to access anatomical locations that were difficult or impossible to reach through minimally invasive procedures.

PLSG president John Manzetti said: "I couldn't be more pleased or more proud of Medrobotics.

"The system offers physicians the ability to access anatomical locations that were difficult or impossible to reach through minimally invasive procedures."

"They were founded by PLSG with their first investment back in 2007 and since then, have continued to advance their business and their patient-centric solutions in ways that will make a tremendous impact on our society."

Designed to quickly integrate into the OR and the surgeon's practice, the system allows hospitals to expand the patient population that they serve and improve the productivity of their facilities.

Medrobotics president Dr Samuel Straface said: "They recognised not only the potential of our company, but also the Flex Robotics system early-on and have been a key proponent in providing the resources we needed to help us deliver our innovative technology to the masses."

Capable of navigating nearly a 180° path to reach challenging surgical targets, the 3mm articulating instruments can be deployed from a stable surgical platform that extends surgeons' reach to perform procedures.

The system also features onboard HD visualisation to provide surgeons with a clear view of the navigation path and surgical site, as well as two working channels to accept a broad spectrum of surgical and interventional instruments.